Actively Recruiting
Evaluate the Possible Efficacy and Safety of Empagliflozin in Patient With Ulcerative Colitis
Led by Tanta University · Updated on 2025-07-16
60
Participants Needed
1
Research Sites
204 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
•This study will be a randomized, controlled, parallel study. .To demonstrate the efficacy of empagliflozin and clinical improvement in patients of mild to moderate UC using the Montreal classification of severity of ulcerative colitis.
CONDITIONS
Official Title
Evaluate the Possible Efficacy and Safety of Empagliflozin in Patient With Ulcerative Colitis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with mild to moderate ulcerative colitis diagnosed by history and clinical signs according to the Montreal classification
- Diagnosis confirmed by endoscopy and biopsy to establish chronic inflammation and exclude other causes of colitis
- Age between 18 and 70 years
You will not qualify if you...
- Other inflammatory bowel diseases such as Crohn's disease
- History of serious hypersensitivity to empagliflozin or any component of the medication
- Patients undergoing dialysis
- Severe kidney impairment with eGFR less than 20 ml/min/1.73m2
- Chronic urinary tract infection
- Chronic genital infection
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Gastroenterology and Endoscopy Unit, Internal Medicine Department, Tanta University Hospital.
Tanta, Egypt
Actively Recruiting
Research Team
Y
youmna H eldeeb, phD
CONTACT
S
Sahar M Elhaggar
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here